Please assess the completion status of the following clinical trial:

Trial Title: Rosuvastatin Effect on Serial Echocardiographic Measurement of Coronary Flow Velocity Reserve

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Controlled Hypertension: treated SBP \< 140 mmHg and DBP \< 90 mmHg~* LDL cholesterol \> 130 mg/dL~* Patients with statin-naive state, defined as receiving no statin therapy for more than 3 months during the previous 12 months~* Any 1 of these cardiovascular risk factors required: smoking, Type 2 DM, age over 55 (men) or 65 (women), peripheral vascular disease, history of cerebrovascular event, family history of early CHD before age 55, HDL cholesterol \< 40 mg/dL~Exclusion Criteria:~* A previous history of intolerance or hypersensitivity to statins~* Uncontrolled hypertension; SBP ≥ 140 mmHg or DBP ≥ 90 mmHg~* Previous MI or currently treated angina pectoris~* Stroke, Transient ischemic attack \< 3 months~* Secondary hypertension~* Fasting serum triglyceride \> 500 mg/dL~* Clinical congestive heart failure~* Uncontrolled arrhythmia~* Left ventricular hypertrophy: LV mass index \> 134g/m2 (male) or \>110g/m2 (female)~* Concomitant clinically important respiratory, hematological, gastrointestinal, hepatic, renal or other disease~* Pregnant or lactating women and those of child-bearing potential

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Rosuvastatin (Type: EXPERIMENTAL): Rosuvastatin 10mg qd for 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).